Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats

Abstract Mild traumatic brain injury (mTBI) is a major public health issue, representing 75–90% of all cases of TBI. In clinical settings, mTBI, which is defined as a Glascow Coma Scale (GCS) score of 13–15, can lead to various physical, cognitive, emotional, and psychological-related symptoms. To date, there are no pharmaceutical-based therapies to manage the development of the pathological deficits associated with mTBI. In this study, the neurotrophic and neuroprotective properties of glucose-dependent insulinotropic polypeptide (GIP), an incretin similar to glucagon-like peptide-1 (GLP-1), was investigated after its steady-state subcutaneous administration, focusing on behavior after mTBI in an in vivo animal model. The mTBI rat model was generated by a mild controlled cortical impact (mCCI) and used to evaluate the therapeutic potential of GIP. We used the Morris water maze and novel object recognition tests, which are tasks for spatial and recognition memory, respectively, to identify the putative therapeutic effects of GIP on cognitive function. Further, beam walking and the adhesive removal tests were used to evaluate locomotor activity and somatosensory functions in rats with and without GIP administration after mCCI lesion. Lastly, we used immunohistochemical (IHC) staining and Western blot analyses to evaluate the inflammatory markers, glial fibrillary acidic protein (GFAP), amyloid-β precursor protein (APP), and bone marrow tyrosine kinase gene in chromosome X (BMX) in animals with mTBI. GIP was well tolerated and ameliorated mTBI-induced memory impairments, poor balance, and sensorimotor deficits after initiation in the post-injury period. In addition, GIP mitigated mTBI-induced neuroinflammatory changes on GFAP, APP, and BMX protein levels. These findings suggest GIP has significant benefits in managing mTBI-related symptoms and represents a novel strategy for mTBI treatment.

[1]  Y. Gustafson,et al.  Traumatic brain injury and young onset dementia: A nationwide cohort study , 2014, Annals of neurology.

[2]  N. Greig,et al.  Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders , 2012, British journal of pharmacology.

[3]  A. Marmarou,et al.  A fluid percussion model of experimental brain injury in the rat. , 1987, Journal of neurosurgery.

[4]  Y. Kang,et al.  Age-dependent alterations in cAMP signaling contribute to synaptic plasticity deficits following traumatic brain injury , 2013, Neuroscience.

[5]  L. J. Eldik,et al.  Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury , 2008, Journal of Neuroinflammation.

[6]  P. Dash,et al.  Altered regulation of protein kinase a activity in the medial prefrontal cortex of normal and brain-injured animals actively engaged in a working memory task. , 2015, Journal of neurotrauma.

[7]  A. Hyder,et al.  The impact of traumatic brain injuries: a global perspective. , 2007, NeuroRehabilitation.

[8]  M. Sofroniew,et al.  Astrocytes: biology and pathology , 2009, Acta Neuropathologica.

[9]  A. Verkhratsky,et al.  Astrocytes in Alzheimer’s disease , 2010, Neurotherapeutics.

[10]  Huan‐Xin Chen,et al.  Effects of glucose-dependent insulinotropic peptide on behavior , 2006, Peptides.

[11]  J. Egan,et al.  Does GLP-1 suppress its own basal secretion? , 2016, Endocrine research.

[12]  D. Graham,et al.  β-Amyloid precursor protein (βAPP) as a marker for axonal injury after head injury , 1993, Neuroscience Letters.

[13]  N. Greig,et al.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury , 2014, Alzheimer's & Dementia.

[14]  P. Bickford,et al.  Long-Term Upregulation of Inflammation and Suppression of Cell Proliferation in the Brain of Adult Rats Exposed to Traumatic Brain Injury Using the Controlled Cortical Impact Model , 2013, PloS one.

[15]  J. Sweeney,et al.  White matter integrity and cognition in chronic traumatic brain injury: a diffusion tensor imaging study. , 2007, Brain : a journal of neurology.

[16]  G. Tesco,et al.  Molecular mechanisms of cognitive dysfunction following traumatic brain injury , 2013, Front. Aging Neurosci..

[17]  G. Clifton,et al.  Prolonged memory impairment in the absence of hippocampal cell death following traumatic brain injury in the rat , 1990, Brain Research.

[18]  S. Brett,et al.  Mechanisms of injury by explosive devices. , 2007, Anesthesiology clinics.

[19]  N. Marklund,et al.  Traumatic axonal injury in the mouse is accompanied by a dynamic inflammatory response, astroglial reactivity and complex behavioral changes , 2013, Journal of Neuroinflammation.

[20]  N. Greig,et al.  Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice , 2012, AGE.

[21]  N. Greig,et al.  Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. , 2003, Diabetes care.

[22]  N. Otsuka,et al.  Rapid appearance of β-amyloid precursor protein immunoreactivity in damaged axons and reactive glial cells in rat brain following needle stab injury , 1991, Brain Research.

[23]  A. Raabe,et al.  GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. , 2004, Journal of neurotrauma.

[24]  H. Levin,et al.  Cognitive function outcomes after traumatic brain injury. , 1998, Current opinion in neurology.

[25]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[26]  N. Irwin,et al.  C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. , 2008, Biochemical pharmacology.

[27]  S. Shapiro,et al.  Diagnosing and Treating Mild Traumatic Brain Injury in Children , 2011, Advanced emergency nursing journal.

[28]  J. Holst,et al.  Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. , 2004, Diabetes.

[29]  D. Graham,et al.  Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. , 1993, Neuroscience letters.

[30]  Brian J Cummings,et al.  Early association of reactive astrocytes with senile plaques in Alzheimer's disease , 1995, Experimental Neurology.

[31]  N. Greig,et al.  Apoptotic and behavioral sequelae of mild brain trauma in mice , 2007, Journal of neuroscience research.

[32]  B. Romner,et al.  Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury , 2015, PloS one.

[33]  N. Irwin,et al.  Effects of glucose-dependent insulinotropic polypeptide receptor knockout and a high-fat diet on cognitive function and hippocampal gene expression in mice. , 2015, Molecular medicine reports.

[34]  C. Bailey,et al.  Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. , 2005, Journal of medicinal chemistry.

[35]  R. Walz,et al.  Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases , 2010, Behavioural pharmacology.

[36]  K. Blennow,et al.  Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome , 2006, Journal of the Neurological Sciences.

[37]  N. Greig,et al.  Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice , 2013, Experimental Neurology.

[38]  N. Greig,et al.  A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. , 2002, The Journal of pharmacology and experimental therapeutics.

[39]  T D Koepsell,et al.  The association between head trauma and Alzheimer's disease. , 1990, American journal of epidemiology.

[40]  C. Mcintosh,et al.  Glucose-Dependent Insulinotropic Polypeptide-Mediated Up-Regulation of β-Cell Antiapoptotic Bcl-2 Gene Expression Is Coordinated by Cyclic AMP (cAMP) Response Element Binding Protein (CREB) and cAMP-Responsive CREB Coactivator 2 , 2007, Molecular and Cellular Biology.

[41]  P. Eriksson,et al.  Glucose-Dependent Insulinotropic Polypeptide Is Expressed in Adult Hippocampus and Induces Progenitor Cell Proliferation , 2005, The Journal of Neuroscience.

[42]  T. Wyss-Coray,et al.  Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. , 2003, Nature medicine.

[43]  C. Hölscher,et al.  Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. , 2008, Journal of neurophysiology.

[44]  N. Irwin,et al.  A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores. , 2013, Biochimica et biophysica acta.

[45]  Kristine Yaffe,et al.  Dementia risk after traumatic brain injury vs nonbrain trauma: the role of age and severity. , 2014, JAMA neurology.

[46]  G. Taglialatela,et al.  Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition , 2009, Behavioural Brain Research.

[47]  Chen-Yang Hsu,et al.  Increased Risk of Dementia in Patients with Mild Traumatic Brain Injury: A Nationwide Cohort Study , 2013, PloS one.

[48]  N. Tajiri,et al.  Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities , 2015, Neuropsychiatric disease and treatment.

[49]  K. Furukawa,et al.  Potential correlation between plasma total GIP levels and body mass index in Japanese patients with types 1 or 2 diabetes mellitus. , 2012, Endocrine journal.

[50]  Douglas H. Smith,et al.  Axonal pathology in traumatic brain injury , 2013, Experimental Neurology.

[51]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[52]  J. Langlois,et al.  Traumatic brain injury in the United States; emergency department visits, hospitalizations, and deaths , 2006 .

[53]  C. Borlongan,et al.  Insulin-associated neuroinflammatory pathways as therapeutic targets for traumatic brain injury. , 2014, Medical hypotheses.

[54]  J. Ponsford,et al.  Long-term outcomes after uncomplicated mild traumatic brain injury: a comparison with trauma controls. , 2011, Journal of neurotrauma.

[55]  R. Parenti,et al.  Gastric inhibitory polypeptide and its receptor are expressed in the central nervous system and support neuronal survival. , 2011, Central nervous system agents in medicinal chemistry.

[56]  T. Beems,et al.  GFAP and S100B are biomarkers of traumatic brain injury , 2010, Neurology.

[57]  D. Graham,et al.  Apoptosis after traumatic brain injury. , 2000, Journal of neurotrauma.

[58]  W. Chiu,et al.  Hyaluronic acid inhibits the glial scar formation after brain damage with tissue loss in rats. , 2009, Surgical neurology.

[59]  N. Greig,et al.  Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases , 2011 .

[60]  S. Bloom,et al.  Gut hormones as therapeutic agents in treatment of diabetes and obesity. , 2013, Current opinion in pharmacology.

[61]  D. Diamond,et al.  Influence of Post-Traumatic Stress Disorder on Neuroinflammation and Cell Proliferation in a Rat Model of Traumatic Brain Injury , 2013, PloS one.

[62]  M. Oddy,et al.  Social recovery during the year following severe head injury. , 1980, Journal of neurology, neurosurgery, and psychiatry.

[63]  C. Hölscher.  The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[64]  C. Hölscher,et al.  Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. , 2011, Journal of neurophysiology.

[65]  H. Shih,et al.  Location and Level of Etk Expression in Neurons Are Associated with Varied Severity of Traumatic Brain Injury , 2012, PloS one.

[66]  N. Greig,et al.  Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats , 2013, PloS one.

[67]  Kristine Yaffe,et al.  Epidemiology of mild traumatic brain injury and neurodegenerative disease , 2015, Molecular and Cellular Neuroscience.

[68]  D. Arciniegas,et al.  Mild traumatic brain injury: a neuropsychiatric approach to diagnosis, evaluation, and treatment , 2005, Neuropsychiatric disease and treatment.

[69]  A. Klegeris,et al.  The Role of Insulin and Incretins in Neuroinflammation and Neurodegeneration , 2014 .

[70]  M. Mattson,et al.  Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells , 2010, Journal of neurochemistry.

[71]  M. Mattson,et al.  GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism , 2009, Proceedings of the National Academy of Sciences.

[72]  D. Westaway,et al.  New developments in animal models of Alzheimer’s disease , 2001, Current neurology and neuroscience reports.

[73]  N. Marchionni,et al.  Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. , 2009, European journal of endocrinology.

[74]  N. Horwood,et al.  Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkapp}B activity. , 2008, Blood.

[75]  Glen T Prusky,et al.  Reduced visual acuity impairs place but not cued learning in the Morris water task , 2000, Behavioural Brain Research.

[76]  D. Cifu,et al.  Assessment and treatment of common persistent sequelae following blast induced mild traumatic brain injury. , 2011, NeuroRehabilitation.

[77]  Y. Ihara,et al.  Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. , 1998, The American journal of pathology.

[78]  G. Wenk.  Assessment of Spatial Memory Using the Radial Arm Maze and Morris Water Maze , 2004, Current protocols in neuroscience.

[79]  V. Perry,et al.  Microglia in neurodegenerative disease , 2010, Nature Reviews Neurology.

[80]  J. Pickard,et al.  Microdialysis of cytokines: methodological considerations, scanning electron microscopy, and determination of relative recovery. , 2009, Journal of neurotrauma.

[81]  M. Mattson,et al.  GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[82]  K. Marder,et al.  Alzheimer's disease after remote head injury: an incidence study. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[83]  B. Gedulin,et al.  A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents , 2013, Diabetes, obesity & metabolism.

[84]  T. Nyström,et al.  Glucagon-Like Receptor 1 Agonists and DPP-4 Inhibitors: Potential Therapies for the Treatment of Stroke , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[85]  D. Drucker,et al.  Pharmacology, physiology, and mechanisms of incretin hormone action. , 2013, Cell metabolism.

[86]  N. Greig,et al.  Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice , 2015, Journal of neurochemistry.

[87]  N. Greig,et al.  Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease , 2012, Journal of Neuroinflammation.

[88]  G. Lazzarino,et al.  Biochemical and neurochemical sequelae following mild traumatic brain injury: summary of experimental data and clinical implications. , 2010, Neurosurgical focus.

[89]  Jinhui Chen,et al.  Mild Traumatic Brain Injury Results in Extensive Neuronal Degeneration in the Cerebral Cortex , 2011, Journal of neuropathology and experimental neurology.

[90]  Mark Bayley,et al.  Clinical practice guidelines for mild traumatic brain injury and persistent symptoms. , 2012, Canadian family physician Medecin de famille canadien.

[91]  P. Kochanek,et al.  One-year study of spatial memory performance, brain morphology, and cholinergic markers after moderate controlled cortical impact in rats. , 1999, Journal of neurotrauma.

[92]  J. Holst,et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[93]  T. Coughlan,et al.  Social adjustment after closed head injury: a further follow-up seven years after injury. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[94]  T. Jones,et al.  Functional subdivisions of the rat somatic sensorimotor cortex , 1990, Behavioural Brain Research.

[95]  E. J. Green,et al.  Hippocampally dependent and independent chronic spatial navigational deficits following parasagittal fluid percussion brain injury in the rat , 1997, Brain Research.

[96]  M. Oddy,et al.  Subjective impairment and social recovery after closed head injury. , 1978, Journal of neurology, neurosurgery, and psychiatry.

[97]  Y.-J. Guo,et al.  Active Immunization with Glucose‐Dependent Insulinotropic Polypeptide Vaccine Influences Brain Function and Behaviour in Rats , 2010, Scandinavian journal of immunology.

[98]  Yuichiro Yamada,et al.  Sensory and motor physiological functions are impaired in gastric inhibitory polypeptide receptor‐deficient mice , 2013, Journal of diabetes investigation.

[99]  M. Mattson,et al.  Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis , 2012, PloS one.

[100]  H. Bramlett,et al.  Modulation of the cAMP signaling pathway after traumatic brain injury , 2007, Experimental Neurology.

[101]  K. Alitalo,et al.  Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing. , 2004, Molecular biology of the cell.

[102]  Bin Yang,et al.  Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans , 2013, Science Translational Medicine.

[103]  T. Wieloch,et al.  Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: 1998. , 1998, Journal of neurotrauma.

[104]  R. Swanson,et al.  Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor , 2012, Journal of Neuroinflammation.

[105]  H. Müller,et al.  Glucose‐dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): Cellular localization, lesion‐affected expression, and impaired regenerative axonal growth , 2009, Journal of neuroscience research.

[106]  D. Loane,et al.  Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention , 2012, Brain, Behavior, and Immunity.